NCT05574049 (THCV) is a EARLY_PHASE1 clinical trial of Tetrahydrocannabivarin in Metabolic Syndrome, sponsored by Medical Life Care Planners, LLC.

Who is sponsoring NCT05574049?

NCT05574049 is sponsored by Medical Life Care Planners, LLC.

What drugs are being tested in NCT05574049?

Interventions in NCT05574049: Tetrahydrocannabivarin, Placebo.

What condition does NCT05574049 study?

NCT05574049 studies Metabolic Syndrome, Morbid Obesity, Hypercholesterolemia, Hyperglycemia.

Is NCT05574049 still recruiting?

NCT05574049 is currently completed. Last updated 10 October 2022.

Last reviewed 2022-10-10 · How we verify

NCT05574049: THCV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Weight Loss, Blood Sugar and Blood Lipid Effects of Tetrahydrocannabivarin (THCV) Impregnated Mucoadhesive Strips

Completed EARLY_PHASE1 Last updated 10 October 2022

What this trial tests

EARLY_PHASE1 trial testing Tetrahydrocannabivarin in Metabolic Syndrome in 56 participants. Completed in 4 May 2022.

Timeline

4 January 2022

Primary endpoint
4 May 2022

4 May 2022

Quick facts

Lead sponsor	Medical Life Care Planners, LLC
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	56
Start date	4 January 2022
Primary completion	4 May 2022
Estimated completion	4 May 2022
Sites	1 location across United States

Drugs / interventions tested

Tetrahydrocannabivarin — full drug profile →
Placebo

Conditions studied

Metabolic Syndrome — all drugs for Metabolic Syndrome →
Morbid Obesity — all drugs for Morbid Obesity →
Hypercholesterolemia — all drugs for Hypercholesterolemia →
Hyperglycemia — all drugs for Hyperglycemia →

Sponsor

Medical Life Care Planners, LLC — full company profile →

Who can join

Adults 18 to 100, any sex, with Metabolic Syndrome or Morbid Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the efficacy of two different daily doses of tetrahydrocannabivarin impregnated mouth strips in healthy non-diabetic obese adults. The main questions to answer are: * Is the low dose treatment superior to placebo for losing weight, abdominal girth, cholesterol levels and blood glucose levels? * Is the low dose treatment superior to placebo for losing weight, abdominal girth, cholesterol levels and blood glucose levels? * Is one dose better than the other dose? Participants will take either the low dose, high dose or placebo dose daily for ninety days and have physical measurements and blood tests obtained at the beginning and the end of the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.
Smith GL. · · 2025 · cited 2× · PMID 39968488 · DOI 10.26828/cannabis/2024/000206

Verify or expand the search:

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting

Other Medical Life Care Planners, LLC trials

Trials by the same sponsor.

NCT06722898 — Rapid BAC Reduction with Nutraceutical Blend Study · Phase 2 · not yet recruiting
NCT06417983 — Topical Application of Essential Oils to Treat Onchomycosis · not yet recruiting
NCT06003062 — Suppression of Upper Lip Hair Growth Using Novel Hemp Extract · unknown
NCT05734703 — Skin Rejuvenation With Topical Extract and Other Nutraceuticals · EARLY_PHASE1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05574049 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical Life Care Planners, LLC
Last refreshed: 10 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05574049.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing